Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JL16
- Development stage
- Preclinical
- Lead developer
- Shandong University
01
Overview
JL16: sourced facts only. name: "Among these, JL16 and JL18 emerged as potent inhibitors of AKT1 kinase, with IC50 values of 7.1 ± 1.2 nM and 8.8 ± 1.3 nM, respectively." [PMID:40020427]; target: "Among these, JL16 and JL18 emerged as potent inhibitors of AKT1 kinase, with IC50 values of 7.1 ± 1.2 nM and 8.8 ± 1.3 nM, respectively." [PMID:40020427]; developer: "Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, PR China." [PMID:40020427]; stage: "Both compounds also demonstrated significant antiproliferative effects against PC-3 prostate cancer cells, with IC50 values of 2.9 ± 0.7 μM (JL16) and 3.0 ± 0.6 μM (JL18)." [PMID:40020427]
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)
Beyond the preview
Go deeper on JL16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JL16.